持续升温——2024 SABCS中国专家壁报展示第四弹！|her2|乳腺癌|介导|壁报|报告人|肿瘤

2024 SABCS

2024年圣安东尼奥乳腺癌学术研讨会（SABCS）将于2024年12月10至13日在美国德克萨斯州圣安东尼奥举行。SABCS官网已披露入选本次大会的摘要标题，医脉通小编为您汇总大会相关信息，精选中国专家报告内容，往期传送：

本期将继续为读者带来Poster Session 4（壁报展示4）部分，医脉通与您携手领略中国专家风采！

医脉通小编与您相约圣安东尼奥Henry B. Gonzalez会议中心（地址：900 E. Market Street, San Antonio, TX 78205 USA），为您带来一手资讯！敬请关注医脉通乳腺肿瘤，共享乳腺癌领域最新进展！

Henry B. Gonzalez Convention Center

中国专家壁报展示专场日期及时间一览，跟随医脉通，共享学术盛宴！

Poster Sessions时间轴

Poster Session 4

壁报展示4

当地时间：2024/12/12 17:30-19:00

北京时间：2024/12/13 7:30-9:00

位置：Halls 2-3

P4-01-18

NEDD9 expression as an indicator for pathologicalcomplete response(pCR)in early-stage HER2-positive breastcancer patients undergoing neoadjuvant therapy

NEDD9表达作为接受新辅助治疗的早期HER2阳性乳腺癌患者病理完全缓解（pCR）的指标

报告人：Bei Jiang

P4-01-23

Potential prognostic Value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer

HER2/CEP17 FISH比值在HER2阳性非转移性乳腺癌中的潜在预后价值

报告人：Fangchao Zheng

P4-01-30

Proteogenomic profiles of HER2-positive breast cancerand response to neoadjuvant anti-HER2 treatment

HER2阳性乳腺癌的蛋白质基因组学特征和对新辅助抗HER2治疗的反应

报告人：Kang Wang

P4-02-19

Development and Validation of a Genetic RiskPrediction Model for Breast Cancer: The Prognostic Role of SNAl1and CDH1 in Treatment Response and Patient Survival

乳腺癌遗传风险预测模型的开发和验证：SNAl1和CDH1在治疗反应和患者生存中的预后作用

报告人：Chieh-Ni Kao

P4-02-20

Investigating Age-Dependent Breast Cancer Dynamicsin a Mouse Model

研究小鼠模型中的年龄依赖性乳腺癌动力学

报告人：Yun Zhang

P4-02-21

Disparities among patients evaluated in dedicated high-risk breast cancer clinic

在专科高危乳腺癌诊所评估的患者间差异

报告人：Helen Yuan

P4-02-25

Dietary-Restriction Genes as Modulators of Breast Cancer Risk Through Metabolic Pathways

饮食限制基因作为代谢途径乳腺癌风险的调节者

报告人：Yiyin Zhang

P4-03-08

Pre-and post-diagnostic healthy lifestyle andcardiovascular disease among breast cancer survivors

乳腺癌幸存者的诊断前和诊断后健康生活方式和心血管疾病

报告人：刘强（中山大学孙逸仙纪念医院）

P4-03-15

Clinical characterization of taxanes chemotherapeuticregiments-induced peripheral neurotoxicity and establishment ofa risk model

紫杉烷类化疗方案诱导的周围神经毒性的临床特征和风险模型的建立

报告人：Bin Yang

P4-03-22

Inhibiting JNKsignaling enhances the antitumor efficacyof macrophage-targeting agents in triple-negative breast cancerby inducing an immunoactive tumor microenvironment

抑制JNK信号传导通过诱导免疫活性肿瘤微环境增强三阴性乳腺癌中巨噬细胞靶向剂的抗肿瘤疗效

报告人：Xuemei Xie

P4-03-30

GPR56/ADGRG1 promotes the progression of triple.negative breast cancer by enhancing PKM2/LDH-mediatedglycolysis via the PI3K/AKT/mTOR/HIF-1a pathway

GPR56/ADGRG1通过PI3K/AKT/mTOR/HIF-1a通路增强 PKM2/LDH 介导的糖酵解，促进三阴性乳腺癌的进展

报告人：Haizhu Chen

P4-04-21

Frozen gloves can prevent chemotherapy-induced nailpigmentation of the hand in early-stage breast cancer patients: aprospective self-matched case-control study

冷冻手套可以防止早期乳腺癌患者化疗引起的手部甲色素沉着：一项前瞻性自我匹配病例对照研究

报告人：Fei Xu

P4-04-22

lmpact of screening mammography on breast canceroutcomes in women aged 80 and over

乳腺X线摄影筛查对80岁及以上女性乳腺癌结局的影响

报告人：Siu-Yuan Huang

P4-04-23

Reverse-sequence Endoscopic Versus ConventionalOpen Nipple-Sparing Mastectomy with lmplant-based BreastReconstruction:A Single-center Prospective Cohort Study(RECOstudy)

逆序列内窥镜与常规保留的乳房切除术与基于lmplant的乳房重建：一项单中心前瞻性队列研究（RECOstudy）

报告人：Tianyuan Li

P4-04-31

A phase lb/l study of PARPi Mefuparib Hydrochloride(CVL218)in combination with PD-1 inhibitor plus chemotherapy inmetastatic or recurrent triple-negative breast cancer (TNBC)

PARPi盐酸Mefuparib（CVL218）联合PD-1抑制剂加化疗治疗转移性或复发性三阴性乳腺癌（TNBC）的lb/l期研究

报告人：张剑（复旦大学附属肿瘤医院）

P4-04-32

Clinical study of 99mTc-Rituximab combined with dyesdouble tracing for axillary sentinel lymph node biopsy afterneoadjuvant chemotherapy for breast cancer

99mTc-利妥昔单抗联合染料双示法治疗乳腺癌新辅助化疗后腋窝前哨淋巴结活检的临床研究

报告人：Hui Zhang

P4-04-33

Rapid evaluation of fluorescent probes targeting Pan-CKstudy of sentinel lymph node metastasis status in breast cancer

靶向Pan-CK的荧光探针的快速评价乳腺癌前哨淋巴结转移状态的研究

报告人：Jun-Hong Chen

P4-04-35

Thioredoxin-Interacting Protein(TXNlP) as a KeyRegulator of Tumor Growth and Progression

硫氧还蛋白相互作用蛋白（TXNlP）是肿瘤生长和进展的关键调节因子

报告人：Liang Liu

P4-04-37

SS Induces BRCA1 Reduction and Sensitizes BreastCancer Cells to PARP Inhibitor Therapy

SS诱导BRCA1减少并使乳腺癌细胞对PARP抑制剂治疗敏感

报告人：Jiagi Chen

P4-04-41

The impacts of neoadjuvant or adjuvant chemotherapyon surgical complications and cosmetic outcomes of reverse-sequence endoscopic nipple-sparing-mastectomy with immediatebreast reconstruction.

新辅助或辅助化疗对逆序内窥镜保留乳房切除术联合即刻乳房重建手术并发症和美容结局的影响。

报告人：Kawun Chung

P4-04-42

A novel 3D-printed scaffold for patient-specific partialbreast reconstruction：A Prospective, Single-Arm Clinical Trial

用于患者特异性部分乳房重建的新型3D打印支架：一项前瞻性单臂临床试验

报告人：Juliang Zhang

P4-05-20

Development and validation of a combined ultrasound-pathology model to predict axillary status after neoadjuvantsystemic therapyin breast cancer

超声-病理联合模型预测乳腺癌新辅助全身治疗后腋窝状态的开发和验证

报告人：Jue Wang

P4-05-21

Dynamic ctDNA tracking stratifies individual relapse riskfor early triple negative breast cancer patients receivingneoadjuvant chemotherapy

动态ctDNA跟踪对接受新辅助化疗的早期三阴性乳腺癌患者的个体复发风险进行分层

报告人：刘强（中山大学孙逸仙纪念医院）

P4-07-16

First line CDK4/6 inhibitors plus endocrine therapyversus chemotherapy for HR+/HER2-metastatic breast cancerpatients in real world a multicenter YOUNGBC-30 study.

一线CDK4/6抑制剂加内分泌治疗与化疗治疗现实世界中HR+/HER2 转移性乳腺癌患者的一项多中心YOUNGBC-30研究。

报告人：王碧芸（复旦大学附属肿瘤医院）

P4-08-08

Real-world data on cyclin-dependent kinase 4/6inhibitor switching in patients with first-line hormone receptor-positive,HER2-negative metastatic breast cancer

一线激素受体阳性、HER2阴性转移性乳腺癌患者细胞周期蛋白依赖性激酶4/6抑制剂转换的真实世界数据

报告人：Lu Chen

P4-08-11

Linc01588-V4 is UPR-downregulated IncRNA in a PERKdependent manner and estrogen-responsive gene mediated celproliferation and migration of ER+ breast cancer cells

Linc01588-V4以PERK依赖性方式下调UPR下调的IncRNA和雌激素反应基因介导的ER+乳腺癌细胞的细胞增殖和迁移

报告人：Wen Liu

P4-08-13

Evaluating CYP3A4-Mediated Drug Interaction Risks forVepdegestrant,a PROteolysis TArgeting Chimera (PROTAC)Estrogen Receptor (ER)Degrader,in Combination With Cyclin-Dependent Kinase(CDK)4/6 Inhibitors and Everolimus

评价CYP3A4介导的药物相互作用风险Vepdegestrant，一种蛋白水解靶向嵌合体（PROTAC）雌激素受体（ER）降解剂，联合细胞周期蛋白依赖性激酶（CDK）4/6抑制剂和依维莫司

报告人：Weiwei Tan

P4-08-26

Trial in progress：First-in-human phase 1a/1b, dose-escalation/expansion study of BGB-43395(CDK4 selectiveinhibitor) as monotherapy or combination therapy in Chinesepatients with metastatic HR+/HER2-breast cancer & otheradvanced solid tumors

正在进行的试验：首次人体Ia/Ib期，BGB-43395（CDK4选择性抑制剂）作为单一疗法或联合疗法在中国转移性HR+/HER2-乳腺癌和其他晚期实体瘤患者中的剂量递增/扩展研究

报告人：张剑（复旦大学附属肿瘤医院）

P4-09-01

Contrast-enhanced ultrasound traced secondarysentinel lymph nodes in early-stage breast cancer to streamlinesentinel lymph node biopsy----a preliminary study

造影剂增强超声追踪早期乳腺癌的次级前哨淋巴结以简化前哨淋巴结活检——初步研究

报告人：Xiaoling Liu

P4-09-02

Multiparametric MRl and Transfer Learning forPredicting Positive Margins in Breast-Conserving Surgery A Multi-Center Study

多参数MRl和迁移学习预测保乳手术中的阳性切缘：一项多中心研究

报告人：Wenbin Zhou

P4-09-07

（标题尚未公布）

报告人：Hui Dai

P4-09-27

The clinical benefits of CDK 4/6 inhibitors andbiomarkerinteractions on HR+/HER2- advanced breast cancerpatientsan updated pairwise meta-analysis of randomizedcontrolled trials and network meta-analysis

CDK4/6抑制剂和生物标志物相互作用对HR+/HER2-晚期乳腺癌患者的临床益处随机对照试验和网状荟萃分析的更新成对荟萃分析

报告人：Sheng-Fan Wang

P4-10-06

Preclinical characterization of BGB-43395,a potentiabest-in-class CDK4 selective inhibitor with potentpharmacodynamic and anti-tumor activity in HR+HER2- breast cancer models

BGB-43395的临床前表征，BGB-43395是一种在HR+HER2-乳腺癌模型中具有强效药效学和抗肿瘤活性的同类最佳CDK4选择性抑制剂

报告人：Hengrui Zhu

P4-11-06

Neoadjuvant anlotinib plus nab-paclitaxel basedchemotherapyin patients with HER2-negative breast cancer Aprospective,single-arm,single-center, phase ll clinical study

基于安罗替尼联合白蛋白结合型紫杉醇的新辅助化疗治疗HER2阴性乳腺癌患者前瞻性、单臂、单中心、ll期临床研究

报告人：Huimin Meng, TingWang

P4-12-11

Large Oncosomes Loaded with circPEX13 EnhanceOsteoclast Differentiation and Facilitate Breast Cancer BoneMetastasis

加载circPEX13的大瘤小体增强破骨细胞分化并促进乳腺癌骨转移

报告人：Jinpeng Luo

P4-12-14

Updated efficacy and safety of CDK4/6 inhibitors plusendocrine therapies in elderly HR+/HER2- metastatic or advancedbreast cancer patient-levelnetwork meta-analysis

CDK4/6抑制剂联合内分泌治疗老年HR+/HER2-转移性或晚期乳腺癌患者水平网络荟萃分析的疗效和安全性更新

报告人：Yun-Sheng Tai

P4-12-21

Efficacy and Safety of MRG002 in Prior TKl-TreatedHER2 Positive Breast Cancer Patients A Single Arm, Open LabelMulticenter, Phase l Study

MRG002在既往TKl治疗的HER2阳性乳腺癌患者中的疗效和安全性单臂、开放标签、多中心、l 期研究

报告人：刘强（中山大学孙逸仙纪念医院）

P4-12-27

Exploring Stimulation Response of Cisplatin Prodrugsand Integrating Photothermal-Photoacoustic Dual-ModalTheranostics in Triple-Negative Breast Cancer through Ozone-mediated Photothermal Catalytic Nanosystem

探索顺铂前药的刺激反应以及通过臭氧介导的光热催化纳米系统整合光热-光声双模态治疗诊断学治疗三阴性乳腺癌

报告人：郑丹（四川大学华西医院）

备注：排名不分先后，按照摘要号进行排序。本文内容基于SABCS官网发布的信息整理，因目前壁报部分未公布报告者单位，信息可能有遗漏或错误，欢迎留言告知。